FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	.,	

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden

D

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cinffoni Tosoph						2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC								Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Ciaffoni Joseph</u>						[COLL]								X Director		or		10% O	wner
(Last) (First) (Middle)						L · · · J								X	X Officer (give title below)			Other (below)	specify
C/O COLLEGIUM PHARMACEUTICAL, INC.						3. Date of Earliest Transaction (Month/Day/Year)								President and CEO					
100 TECHNOLOGY CENTER DRIVE						11/10/2022													
(Street)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
STOUG	HTON M	A (02072											X	′				
														Form filed by More than One Reporting Person					
(City)	(S	tate) ((Zip)																
		Tab	le I - No	on-Deriv	ative	Sec	uriti	ies Ac	quired	l, Di	sposed o	of, or Be	neficia	lly (Owned	i			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day)					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of (D) (Instr. 3, 4 and 1)				and 5) Securitie Beneficia		es Fo ally (D) Following (I)		vnership i: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										v	Amount	(A) or (D)	Price	l Turinga		tion(s)			(111501.4)
Common Stock 11/18/20					2022	022			M		1,989 A \$		\$15.9	9	325,442			D	
Common Stock 11/18/20					022		S ⁽¹⁾		1,989	D	\$22.02	2.02(2)		23,453		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	re Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)		4. Transac Code (II 8)			6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date		7. Title an Amount o Securities Underlyin Derivative (Instr. 3 ar	f g Security	ount ber		9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				

Explanation of Responses:

\$15.9

Stock Option

(Right to

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022.

M

2. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$22.00 to \$22.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

(3)

1,989

3. All of the 1,989 option shares are exercisable

/s/ Colleen Tupper as Attorney-In-Fact For Joseph Ciaffoni

** Signature of Reporting Person

1,989

\$0

0

Common

Stock

01/25/2029

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

11/18/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.